Navigation Links
Recurrence of aggressive uterine cancer reduced by new form of therapy

The incidence of uterine papillary serous carcinoma (UPSC) has increased since it was first identified in 1981. The condition was initially regarded as easy to treat until about 1990 when a number of persons were diagnosed with the // aggressive cancer. It has remained a significant problem since then.

UPSC is found in higher rates in African American women than in white women. The disease looks like ovarian cancer and spreads just as rapidly, restricting the choice of treatment to only chemotherapy.

A state-of-the-art treatment program now developed at Yale School of Medicine has been found to increase survival from the aggressive uterine papillary serous carcinoma (UPSC) sparing the need for additional therapy in some patients.

According to the study, it has been that a combination of platinum-based chemotherapy and vaginal radiation to be the most effective treatment for the disease. This has infact led to the establishment of a standard of care being established for this type of uterine cancer.

Moreover, it can also be used to evaluate the need for additional treatment following surgery and hence determine the prognosis. The survival rates of women have considerably increased with reduction in the recurrence rates.

The study was conducted on a group of 74 patients with UPSC who underwent complete surgical staging, or hysterectomy with removal of lymph nodes and fat pads. Cancer recurred in 43 percent of early stage patients who did not receive chemotherapy, while in the 20 percent of patients who received platinum-based chemotherapy there were no recurrences. About 14 patients were spared additional radiation treatment.
'"/>




Page: 1

Related medicine news :

1. Lowering Risk of Breast Cancer Recurrence
2. HRT Found To Increase Recurrence of Breast Cancer
3. The Link Between HRT And Recurrence of Breast Cancer
4. Tumour marker for detecting early Recurrence of Thyroid cancer may be soon available
5. Predicting Breast Cancer Recurrence By Understanding Gene Signature
6. Combination Therapy To Avoid Prostate Cancer Recurrence
7. Cervical Cancer Recurrence Risk Even After Removal Of Pre-Cancerous Cells
8. Drugs Are Effective In Treating Depression and Preventing Recurrence
9. PET-CT Scores High On Precision for Diagnosing Ovarian Cancer Recurrence
10. Experts Warn of Bird Flu Recurrence in Maharashtra
11. Petition On Recurrence Of Dengue And Malaria In Kolkata
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... and laboratory-grade deionized water from the same place. From 101 Water Texas, here ... Satisfaction: Patients and staff can enjoy a continuous supply of pure, fresh, oxygenated ...
(Date:4/23/2017)... CA (PRWEB) , ... April 23, 2017 , ... ... solutions and managed services announced the achievement of Cisco Select certification and SMB ... throughout the United States. , In earning the Select Certification, Altura ...
(Date:4/22/2017)... , ... April 22, 2017 ... ... of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its “Woman-Owned ... PROSHRED® Philadelphia specializes in providing information destruction , recycling, and ...
(Date:4/22/2017)... PA (PRWEB) , ... April 22, 2017 , ... ... experience to his role as Vice President of Sales and Business Development at ... key GPO/IDN business partner engagements, business development, and strategic planning for the company. ...
(Date:4/21/2017)... ... 21, 2017 , ... An April 10 article in the Daily ... reveal a great deal about prehistoric ice-age dental practitioners and their primitive and, no ... to remove decayed dental matter, and that teeth were then filled with bitumen, a ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
Breaking Medicine Technology: